Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
TroVax Renal Immunotherapy Survival Trial
NCT00397345 · View on ClinicalTrials.gov ↗
Study Summary
The purpose of this study is to investigate whether TroVax, when added to first line standard of care therapy, improves survival for patients with locally advanced or metastatic clear cell renal adenocarcinoma.
Conditions Studied
Interventions
- BIOLOGICAL Placebo
- BIOLOGICAL Trovax
- BIOLOGICAL Standard of care therapy
Study Locations (20)
California
- La Jolla, CA — La Jolla
- The Angeles Clinic and Reseach Institute — Los Angeles
- 1300 N. Vermont Ave — Los Angeles
- UCLA Urology/Oncology — Los Angeles
- Scripps Cancer Center — San Diego
- Sharp Health Care — San Diego
Florida
- Broward Oncology Associates — Fort Lauderdale
- SCORE Physician Alliance — St. Petersburg
- SCORE Physician Alliance — St. Petersburg
- H. Lee Moffitt Cancer Center & Research Institute — Tampa
Georgia
- Augusta Oncology Associates — Augusta
- SMO-USA Inc. — Canton
Illinois
- Patricia A. Joyce Cancer Institute — Olympia Fields
- Edward H Kaplan and Associates — Skokie
Arizona
- AZ Cancer Center — Tucson
Arkansas
- Little Rock Hematology / Oncology Associates, P.A. — Little Rock
Colorado
- UCHSC — Aurora
District of Columbia
- Washington Cancer Center — Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 733 participants |
| Start Date | 2006-09 |
| Est. Completion | 2009-12 |
| Phase | Phase 3 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00397345
The ClinicalTrials.gov registry entry for NCT00397345 describes a study currently listed as completed. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 733 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Oxford BioMedica, which has 4 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 1 condition, with Clear Cell Renal Carcinoma appearing as the primary indexed condition, and to 3 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00397345 reports 20 study locations spanning 10 distinct geographic areas — top geographies include California, Florida, Georgia. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00397345 about?
NCT00397345 is a clinical study titled "TroVax Renal Immunotherapy Survival Trial". The purpose of this study is to investigate whether TroVax, when added to first line standard of care therapy, improves survival for patients with locally advanced or metastatic clear cell renal adenocarcinoma.
What is the current status of trial NCT00397345?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 733 participants. The study started on 2006-09. Estimated completion is 2009-12.
What conditions does trial NCT00397345 study?
This clinical trial studies the following conditions: Clear Cell Renal Carcinoma. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
What interventions are being tested in trial NCT00397345?
The interventions under investigation include: Placebo (BIOLOGICAL), Trovax (BIOLOGICAL), Standard of care therapy (BIOLOGICAL). Each intervention is being evaluated for safety and efficacy as part of this clinical study.
Who is sponsoring clinical trial NCT00397345?
This trial is sponsored by Oxford BioMedica, which has 4 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00397345 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.